Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References 1, , , , and , “Characteristics of Right Pulmonary Vein With an Epicardial Connection Needing Additional Carina Ablation for Isolation,” Journal of Arrhythmia 39, no. 6 (October 2023): 884–893.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ken Masuda
Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR -mutant non-small cell lung cancer
|
By Ryoko Inaba Higashiyama, Tatsuya Yoshida, Kouya Shiraishi, Jun Miyakoshi, Masahiro Torasawa, Masayuki Shirasawa, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Yukihiro Yoshida, Yasushi Goto, Hidehito Horinouchi, Ryuji Hamamoto, Noboru Yamamoto, Shun-ichi Watanabe, Yasushi Yatabe, Takashi Kohno, Yuichiro Ohe, Takaaki Tuchida
|
Nature
Verified
Abstract Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may improve outcomes in metastatic EGFR-mutant NSCLC, but VEGF inhibitors are not universally effective. We evaluated the impact of VEGFA and VEGFR2 expressions on EGFR-TKI outcomes. EGFR-mutant NSCLC patients from the National Cancer Center Hospital, were retrospectively analysed. The early-stage cohort comprised stage I–IIIA patients (1997–2019).
Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
1 Introduction In recent years, the efficacy of trastuzumab deruxtecan (T-DXd) as a second-line therapy for human epithelial growth factor receptor type 2 (HER2) mutation-positive non-small cell lung cancer (NSCLC) has been demonstrated. HER2 is a receptor tyrosine kinase composed of an extracellular domain, a transmembrane domain (TMD), and a kinase domain [1].
Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes
DFS disease-free survival ECOG-PS Eastern Cooperative Oncology Group performance status IHC immunohistochemistry LS-SCLC limited-stage small cell lung cancer ORR objective response rate OS overall survival PFS progression-free survival SLFN-11 Schlafen 11 1 Background Small cell lung cancer (SCLC) accounts for 14%–15% of all lung cancer diagnoses [1].
Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy
4. Discussion In this study, we performed the whole-exome sequencing of tissues from patients with advanced thymoma to explore the genomic variants related to exceptional responses of pemetrexed monotherapy. We identified certain Indels that were potentially deleterious, including SCN3A, GTF3C1, and RPL5. However, none of the genomic alterations were candidate driver oncogenes, and none were specific to exceptional responders. No novel driver oncogene was identified in advanced thymomas.
McArthur Heights - Kanagawa
McArthur Heights - Stay For Free With Japanese Government Subsidy! It was General Douglas McArthur who upon entering Japan, arranged for a secret getaway from the busy life of the city in a place, just an hour outside of Tokyo, called McArthur Heights where international visitors can now stay for free with the daily subsidy from the Japanese Government beginning on October 11! Nestled in a beautiful bay, sheltered from the open sea, McArthur Heights hosts the McArthur Heights Yacht Club where...
Highlights • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. Abstract Objective Nivolumab and pembrolizumab have been the standard of care in patients with previously treated advanced non-small cell lung cancer (NSCLC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ken
Contact Ken, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack